Business Context and Reporting Period
This Form 8-K filing by Viewbix Inc. (referred to in metadata as Quantum X Labs Inc.) covers events occurring on July 3 and July 4, 2024, with a report date of July 5, 2024. The company, incorporated in Delaware and headquartered in Tel Aviv, Israel, announced two material definitive agreements: a private placement of equity securities and the establishment of a credit facility.
Key Financial Metrics and Transaction Details
Private Placement (July 3, 2024)
- Gross Proceeds: Expected to be $256,875.
- Securities Issued: 1,027,500 shares of common stock and warrants to purchase up to 1,541,250 shares.
- Purchase Price: $0.25 per Unit (share plus warrant).
- Warrant Terms: Exercise price of $0.25 per share; three-year term; subject to automatic exercise upon Nasdaq listing approval.
- Transaction Costs: Lead Investor reimbursement up to $10,000; cash fee of $12,844; issuance of 51,375 shares as commission.
Credit Facility (July 4, 2024)
- Total Facility Amount: $2.5 million.
- Interest Rate: 12% per annum, payable in shares and warrants at a conversion rate of $0.25 per share.
- Drawdown Schedule: $50,000 immediate; $50,000 upon uplisting effectiveness; remaining $2.0 million available quarterly after uplisting until exhausted or a $2.0 million financing transaction is completed.
- Repayment: Due in cash upon completion of a $2.0 million financing transaction or full drawdown.
- Uplist Conversion: Upon uplisting, $100,000 of the loan converts to shares and warrants at $0.25 per share.
- One-Time Fee: Shares representing 5% of the facility amount ($125,000 value at $0.25/share) and a warrant to purchase 1,000,000 shares at $0.25.
Material Changes and Liquidity
The filing does not provide comparative financial statements (revenue, profit, or cash flow) for the current period versus prior periods. The primary material change is the influx of capital through the private placement and the creation of a new debt obligation. The filing indicates the company is seeking to uplist its shares to the Nasdaq Capital Market, a condition tied to specific drawdowns and conversion features of the credit facility.
Guidance, Risks, and Contingencies
- Forward-Looking Statements: The company explicitly states that the potential uplisting to the Nasdaq Capital Market is subject to conditions and contingencies and may not occur.
- Registration Obligations: The company must file resale registration statements for both the private placement and credit facility securities within 30 days of the agreements. Failure to do so or to maintain effectiveness triggers liquidated damages.
- Standstill and Hedging: Investors are subject to a 30-day standstill restriction following the effective date of the registration statement and are prohibited from entering into hedging transactions that establish a net short position while warrants are outstanding.
- Unregistered Securities: The securities issued in these transactions have not been registered under the Securities Act of 1933 and cannot be sold in the U.S. absent registration or an exemption.
Investor Verification Checklist
- Verify the effectiveness of the resale registration statements for the PIPE shares and credit facility securities.
- Confirm the company's progress toward meeting Nasdaq Capital Market listing requirements, as this triggers specific financial obligations and warrant exercises.
- Monitor the drawdown schedule of the $2.5 million credit facility to assess immediate cash flow needs and dilution impact.
- Review the exact terms of the liquidated damages clause regarding registration statement failures.
- Clarify the discrepancy between the metadata company name ("Quantum X Labs Inc.") and the registrant name in the filing ("Viewbix Inc.").